Purpose: Active surveillance is the preferred management of low risk prostate cancer. Cancer specific anxiety during active surveillance remains under studied. We evaluated long-term anxiety in men on active surveillance to determine whether interventions must be tailored to improve adherence. Materials and Methods: A total of 413 men enrolled in active surveillance at a single tertiary care center completed quality of life surveys as part of routine care. A modified version of the MAX-PC (Memorial Anxiety Scale for Prostate Cancer) was used to determine cancer specific anxiety. Generalized estimating equations were applied to evaluate the association between anxiety and the duration on surveillance. Additionally, we examined associations between anxiety and patient age, marital status, Gleason score, the number of positive cores, family history and overall health. Results: Median patient age was 61 years, median prostate specific antigen at diagnosis was 4.4 ng/ml and 95% of the patients had Gleason 6 disease. Median time from the initiation of active surveillance to the last survey was 3.7 years. There was a 29% risk of reporting cancer specific anxiety within year 1. Anxiety significantly decreased with time (OR 0.87, 95% CI 0.79e0.95, p ¼ 0.003). Pathological and demographic characteristics were not associated with anxiety after adjusting for time on surveillance. Conclusions: In men undergoing active surveillance we observed a moderate risk of cancer specific anxiety which significantly decreases with time. Those considering conservative management can be informed that, although it is common to experience some anxiety initially, most patients rapidly adjust and report low anxiety levels within 2 years.
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Subsequently active surveillance has emerged as the preferred treatment strategy in appropriately selected patients with low risk disease. By avoiding or postponing definitive intervention the morbidity and impairments associated with radical treatment are reduced without compromising oncologic safety or cancer specific survival. 2e5 Active surveillance dramatically increased in the United States in the last decade. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
Supported by Sidney Kimmel Center for Prostate and Urologic Cancers SPORE Grant P50-CA92629 from the NCI (National Cancer Institute) (Dr. Recent studies demonstrated no difference in HRQoL and mental health between men undergoing active surveillance and men receiving treatment. 5 However, anxiety was evaluated with generic instruments such as the HADS (Hospital Anxiety and Depression Scale). It is unclear whether these tools are best suited to measure the sort of disease specific anxiety that might be caused by living with untreated prostate cancer. For example, assessments of anxiety may yield different results if men are asked whether they "feel butterflies in their stomach," which is a question found in general anxiety instruments, vs being asked whether they have "distressing worries or thoughts due to their cancer," which is a typical item on disease specific anxiety instruments.
A few studies have appropriately used cancer specific questionnaires such as the MAX-PC in men on active surveillance.
12e14 However, they are limited by small sample sizes, such as 32 patients, and shortterm followup, such as 9 months. At our institution we have integrated patient reported outcomes of prostate cancer into routine clinical practice. For men followed on active surveillance our routine questionnaires include an assessment of cancer related anxiety. This provides data on a large number of patients for many years of followup.
The objective of this study was to estimate the risk of cancer specific anxiety with time in men on active surveillance. Specifically we sought to determine whether prostate cancer related anxiety in an individual changes with time and whether any clinical variables are associated with anxiety.
MATERIALS AND METHODS

Patient Cohort
Following institutional review board approval we identified 463 patients from a longitudinal registry who were enrolled in active surveillance at our institution from 2000 until 2016. Men were eligible for inclusion in the cohort if they were diagnosed with D'Amico low or intermediate risk prostate cancer and underwent repeat biopsy within 6 months of the initial diagnosis. Patients were followed with routine PSA and digital rectal examination every 6 months. Repeat biopsy was recommended within 12 months after initiating active surveillance and every 3 years thereafter. Targeted biopsy was performed in patients with a lesion on magnetic resonance imaging.
Starting in 2013 at our institution the collection of patient reported outcomes was implemented in men undergoing active surveillance via a web based platform. Of the eligible patients 413 had completed surveys assessing current quality of life status. Surveys were administered to patients as part of routine clinical care for all prostate cancer related visits (ie followup/counseling, prostate biopsy or magnetic resonance imaging).
Primary Outcome
Patient reported outcomes of prostate cancer related anxiety were determined by a modified version of the MAX-PC. 15 Men currently on active surveillance were asked 3 questions related to the current level of prostate cancer specific anxiety, including 1) whether prostate cancer impaired the ability to plan for the future, 2) whether prostate cancer resulted in distressing worries or thoughts and 3) whether these thoughts affected mood. Responses to each question were measured on a 5-item Likert scale ranging from strongly agree to strongly disagree. A liberal definition of anxiety was used with responses indicating agreement or strong agreement with any statement resulting in a label of cancer related anxiety. Men were also asked to rank the current overall state of health on a 10-point Likert scale with lower scores indicating poorer overall health.
Statistical Analysis
GEEs were used to estimate the risk of prostate cancer anxiety during active surveillance and ascertain whether the duration of time on active surveillance influenced the risk of anxiety. Additionally, we wished to assess predictors of anxiety levels. We tested the association between anxiety and patient age, marital status, Gleason score on diagnostic biopsy, the number of positive cores on biopsy, family history, visit type (biopsy related vs nonbiopsy related) and overall state of health after adjusting for the interval on active surveillance using separate multivariable GEE regression models. We investigated whether nonlinear terms for time on active surveillance would improve the model fit but they were not significant and, therefore, they were not included in any model. All statistical analyses were completed with StataÒ, version 13.0. Table 1 lists patient characteristics. Median age was 61 years (IQR 56e67) and median PSA at diagnosis was 4.4 ng/ml (IQR 3.3e6.3). Upon the initiation of surveillance approximately 95% of patients had grade group 1 disease (Gleason 6) and the remainder had grade groups 2 and 3 disease (Gleason 7) except 1 Participants completed a median of 2 surveys (IQR 1e3) while on active surveillance. Median time from the start of surveillance to the first and the last survey was 2.8 (IQR 1.7e4.5) and 3.7 years (IQR 2.3e5.4), respectively. Due to the relatively recent implementation of the surveys we did not have more than 3 years of responses from any patient. Therefore, the data are predominately cross-sectional.
RESULTS
To determine the validity of drawing longitudinal inferences from cross-sectional data we tested for an association between the date of AS enrollment and the risk of elevated anxiety after adjusting for time on AS. We found no significant association with the direction of the central estimate corresponding to a decrease in the risk of elevated anxiety in more recent years (1-year increase in the enrollment date OR 0.89, 95% CI 0.74e1.07, p ¼ 0.2).
The figure shows the univariable predicted risk of prostate cancer related anxiety with time on surveillance (per year OR 0.87, 95% CI 0.79e0.95, p ¼ 0.003). After 1 year on active surveillance the estimated risk of anxiety was 29%, which decreased by 14% after 7.5 years.
There was a possible explanation of these findings. If anxious patients gradually quit active surveillance due to anxiety, anxiety levels would appear to fall with an increasing duration of time on surveillance. To evaluate this hypothesis we analyzed data on the reason for discontinuing surveillance. Only 8% of the men who switched to treatment, representing about 2% to 3% of the total cohort, did so for personal reasons. Therefore, selective withdrawal of anxious patients would not explain the 15% or greater absolute decrease in the risk of anxiety with time. Table 2 shows multivariable GEE models adjusted for time on active surveillance. We did not find evidence to suggest that patient age, Gleason score on diagnostic biopsy, the number of positive cores on biopsy, relationship status, family history or visit type were associated with the risk of reporting prostate cancer anxiety after adjusting for time on surveillance (p 0.14, table 2). There was a significant association between overall health scores and cancer related anxiety with a lower risk of anxiety in men who reported a better overall state of health (OR 0.83, 95% CI 0.74e0.93, p ¼ 0.001). Table 3 lists the predicted risks of prostate cancer anxiety by overall health score and time on active surveillance based on the multivariable GEE model. At 5 years men who reported a poor overall health score (4 of 10) had an estimated risk of anxiety more than twice as great than those who reported excellent overall health (score 10 of 10).
DISCUSSION
Using a liberal definition of cancer specific anxiety we identified that a moderate proportion of men initially reported some form of anxiety related to the disease but the risk of anxiety decreased with time. No demographic or clinical variables were associated with cancer specific anxiety during active surveillance except the way that patients ranked overall health.
Only a few studies have investigated how levels of prostate cancer anxiety change during the course of active surveillance. The current published Time from AS to survey (years)
Univariable predicted risk and 95% CI of prostate cancer anxiety by time from active surveillance to survey response date (shaded area) in 413 patients. 12 Punnen et al reported estimates out to 3 years but the sample size was small with only 32 patients reporting scores after 1 year. 13 Anderson et al described anxiety levels in 86 participants but did not present longitudinal data. 14 To our knowledge our study represents the largest sample size with the longest followup of prostate cancer specific anxiety during active surveillance.
Other assessments of HRQoL in men treated conservatively have suggested that overall anxiety and distress levels are generally low in this population.
13, 14 Tan et al found a much lower 14% rate of prostate cancer specific anxiety (MAX-PC score 26 or greater) in men diagnosed up to 1 year previously. 16 The predicted risk of prostate cancer specific anxiety within year 1 in our study was twice as high at 29%. This was likely because we used a much more liberal definition of anxiety. We believe that it is important to note whether a patient declares any form of cancer related anxiety instead of using a sum score and cut point, which has been done in many other studies. Our findings suggest that the degree of cancer specific anxiety is not insignificant and it may be underestimated in the existing literature.
Despite moderate reports of anxiety during the initial survey period there was a clear trend toward decreasing anxiety with time (see figure) . This finding echoes results in a Dutch cohort suggesting that anxiety decreased among men as little as 9 months after initiating active surveillance. 12 Reduced disease related anxiety with time may indicate the importance of maintaining structured and routine followup in the care of men on surveillance. Furthermore, the clear relationship between how patients perceive overall health and reports of disease specific anxiety also mirrored the findings of the Dutch study. 12 Although poor overall health should not preclude men from participating in active surveillance, it should alert members of the health care team to the possibility of a higher likelihood of prostate cancer anxiety. With that said, we cannot exclude reverse causation, that is anxiety led to reduced health rather than the other way around.
To our knowledge a unique aspect of this study was the ability to track survey responses of each patient according to the type of hospital visit. Using the unique, web based platform available at our institution 17 we could ascertain survey data related to the hospital visit of each patient separately by visit type, including routine followup, imaging related or prostate biopsy. To our knowledge this is the first study that has attempted to do so.
We expected that biopsy visits would likely trigger disease related concerns, which may translate to heightened levels of prostate cancer specific anxiety. However, we found no significant association between anxiety levels and the type of clinical visit after adjusting for patient time on active surveillance. Findings of other studies evaluating the psychological impact of prostate biopsy remain variable. In a prospective study of the effect of biopsy on general anxiety in men undergoing PSA screening the investigators identified that the overall level of general anxiety was low. 18 However, in men diagnosed with prostate cancer or those who experience post-biopsy adverse events the level of anxiety was significantly higher. 18, 19 We only assessed HRQoL in relation to clinical encounters. It is plausible that in some men hospital visits may trigger heightened awareness of the disease and translate into greater cancer related anxiety. Future studies may benefit from routine HRQoL assessments of men on active surveillance in settings unrelated to hospital or clinic visits.
Despite the many strengths of this study there are some notable limitations. Our data lacked information on the patient history of anxiety, depression or mental health issues prior to a cancer diagnosis. Although our assessments of disease specific anxiety throughout active surveillance may have adjusted for possible discrepancies in baseline anxiety levels, we could not specifically evaluate whether patients with a history of depression or mental health illnesses differed in any way in regard to HRQoL. Additionally, although our analysis revealed that marital and partner status was not associated with the risk of reporting anxiety, we lacked formal assessments of anxiety in partners. Overall we could not discern the exact influence of partners on the cancer specific anxiety levels of men in this study.
However, the high 81% acceptance rate of active surveillance at our institution 20 mitigated the impact of selection bias. Whether partners induced a positive or a negative impact on psychological HRQoL in patients on active surveillance is an area that warrants further study because the literature remains equivocal. 21 , 22 Furthermore, we did not assess HRQoL following crossover to active treatment to determine whether prostate cancer specific anxiety resolved following definitive intervention. Our study identified moderate anxiety at the beginning of active surveillance. Physicians who counsel men with prostate cancer should inform their patients that these feelings are normal. By applying a systematic approach and normalizing cancer specific anxiety barriers to the acceptance of active surveillance can be overcome. 20 Since anxiety levels decrease with time, interventions specifically aimed at reducing anxiety routinely will have less impact. In our cohort we did not identify risk factors associated with cancer specific anxiety during active surveillance. Therefore, strategies to reduce anxiety in select men should be targeted during the initial diagnosis of prostate cancer since this is likely the critical time point to improve adherence to active surveillance.
CONCLUSIONS
Men with prostate cancer who were followed on active surveillance initially demonstrated moderate levels of disease specific anxiety but these levels decreased with time. Although no clinical or demographic variables were associated with reports of prostate cancer anxiety, men who perceived themselves to have poor overall health reported significantly higher cancer specific anxiety. Patients considering active surveillance can be informed that, although it is expected to experience a certain degree of anxiety at first, most men adjust rapidly and report low anxiety levels within 2 years. These results should be considered when counseling patients and they justify the need for systematic followup during expectant management of prostate cancer.
